secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001213900-24-041325
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q1 net loss narrows to $36.8M; REZPEG Phase 2b on track for H1 2025 data
-------------------------------------------------------------------------------

- Revenue flat at $21.6M; net loss of $36.8M ($0.19/share) vs $137M loss YoY, improved on lower costs.
- Cash and securities $326M; expects to fund operations into Q3 2026.
- R&D expense $27.4M, down from $30.5M YoY; G&A $20.1M vs $21.1M.
- Phase 2b REZPEG studies in atopic dermatitis and alopecia areata enrolling; topline data H1 2025.
- Raised $30M gross via private placement in March 2024 with TCG Crossover Fund.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/0001213900-24-041325-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390024041325/ea0205626-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-041325

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer